Supplementary Table S1. Comparison of general study characteristics of 2006 with 2016 RCTs.

Characteristics	All	Study year		P
	(N = 76)	2006 (N = 34)	2016 (N = 42)	
Funding source				0.305
Industry, full or partial	42 (55.3)	21 (61.8)	21 (50)	
Non-profit or unspecified	34 (44.7)	13 (38.2)	21 (50)	
Study phase				0.327
Phase 2	11 (14.5)	3 (8.8)	8 (19)	
Non-phase 2/unspecified	65 (85.5)	31 (91.2)	34 (81)	
Experimental intervention				0.123
Traditional DMARD	8 (10.5)	5 (14.7)	3 (7.1)	
Biologic DMARD	38 (50)	17 (50)	21 (50)	
Small molecule	4 (5.3)	0 (0)	4 (9.5)	
Others	26 (34.2)	12 (35.3)	14 (33.3)	
Number of study arms				0.381
2	40 (52.6)	16 (47.1)	24 (57.1)	
>2	36 (47.4)	18 (52.9)	18 (42.9)	
Placebo arm, yes	45 (59.2)	15 (44.1)	30 (71.4)	0.016
Study centers, multiple	57 (75)	26 (76.5)	31 (73.8)	0.790
Study duration, months	6 (3-12)	9 (4.5-12)	6 (3-12)	0.275
Efficacy, positive*	59 (80.9)	28 (84.8)	31 (77.5)	0.427

Values represent number (%) for categorical & median (25^{th}-75^{th} percentile) for the numeric variables.
*: N = 73, 3 RCTs excluded as were strategy trials with no intervention declared as experimental a priori.
DMARD: disease modifying anti-rheumatic drug; N: total number; P: p-value; RCT: randomized controlled trial.

Supplementary Table S2. Differential attrition. Percentage of subjects in 2006 & 2016 RCTs not completing the trial in each study arm.

Percent patients with missing outcome	**Experimental intervention arm** (N = 68)[1]	**Active comparator arm** (N = 26)[2]	**Placebo comparator arm** (N = 41)[3]
< 5%	13 (19.1)	4 (15.4)	4 (9.8)
5-10%	9 (13.2)	7 (26.9)	4 (9.8)
>10-20%	30 (44.1)	7 (26.9)	16 (39)
>20%	16 (23.5)	8 (30.8)	17 (41.5)

[1]: Information about subjects completing trial missing for 8/73 RCTs in the experimental interventional arm (3 RCT had no missing data). [2]: Information about subjects completing trial missing for 5/31 RCTs with active comparator arm. [3]: Information about subjects completing trial missing for 4/45 for placebo control arm